Business Description
Xeris Biopharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US98422L1070
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | -0.03 | |||||
Debt-to-Equity | -29.28 | |||||
Debt-to-EBITDA | -10.87 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -1.62 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 35.5 | |||||
3-Year EBITDA Growth Rate | 54.7 | |||||
3-Year EPS without NRI Growth Rate | 39.8 | |||||
3-Year FCF Growth Rate | 42.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 17.01 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 27.87 | |||||
9-Day RSI | 37.45 | |||||
14-Day RSI | 43.44 | |||||
6-1 Month Momentum % | -0.2 | |||||
12-1 Month Momentum % | -13.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 1.81 | |||||
Cash Ratio | 1.2 | |||||
Days Inventory | 457.07 | |||||
Days Sales Outstanding | 78.24 | |||||
Days Payable | 135.4 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.3 | |||||
Shareholder Yield % | -21.36 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 82.9 | |||||
Operating Margin % | -26.25 | |||||
Net Margin % | -37.58 | |||||
FCF Margin % | -25.39 | |||||
ROE % | -1019.2 | |||||
ROA % | -19.67 | |||||
ROIC % | -20.86 | |||||
ROC (Joel Greenblatt) % | -123.92 | |||||
ROCE % | -15.53 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.68 | |||||
EV-to-EBIT | -12.92 | |||||
EV-to-EBITDA | -19.81 | |||||
EV-to-Revenue | 2.86 | |||||
EV-to-Forward-Revenue | 2.61 | |||||
EV-to-FCF | -11.29 | |||||
Earnings Yield (Greenblatt) % | -7.74 | |||||
FCF Yield % | -14.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Xeris Biopharma Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 158.45 | ||
EPS (TTM) (€) | -0.425 | ||
Beta | 0 | ||
Volatility % | 62.46 | ||
14-Day RSI | 43.44 | ||
14-Day ATR (€) | 0.046824 | ||
20-Day SMA (€) | 2.0188 | ||
12-1 Month Momentum % | -13.73 | ||
52-Week Range (€) | 1.36 - 2.96 | ||
Shares Outstanding (Mil) | 148.26 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xeris Biopharma Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xeris Biopharma Holdings Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Xeris Biopharma Holdings Inc Frequently Asked Questions
What is Xeris Biopharma Holdings Inc(FRA:2B30)'s stock price today?
When is next earnings date of Xeris Biopharma Holdings Inc(FRA:2B30)?
Does Xeris Biopharma Holdings Inc(FRA:2B30) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |